ClinicalTrials.gg
RecruitingNCT07739186Updated Nov 12, 2026

A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)

A Phase 2/3 interventional study of BL-B01D1 and PD-1/VEGF Bispecific Antibody in Non-squamous Non-small Cell Lung Cancer, sponsored by Sichuan Baili Pharmaceutical Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Sichuan Baili Pharmaceutical Co., Ltd. (part of Sichuan Biokin Pharmaceutical Co., Ltd.) · Phase 2/3, Interventional, and Treatment

Updated Nov 12, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing izalontamab brengitecan in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 18 under way, 9 of them phase 3. izalontamab brengitecan · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
13th of 18
166 · median 417
Started
2026
with 5 others
Phase 2/3
4 of 18
4 open now
Primary completion
2029-12
later than 11 of 17 live
Registered
16th of 18
by date
Lead sponsor
13 of 18
Sichuan Baili Pharmaceutical Co., Ltd.

Among the 18 studies testing izalontamab brengitecan in Carcinoma, Non-Small-Cell Lung, this one is the 13th largest by planned enrollment, is one of 6 that started in 2026, is one of 4 in phase 2/3, reaches primary completion later than 11 of the 17 other live ones, and was the 16th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

13 of the 18 studies testing izalontamab brengitecan in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About izalontamab brengitecan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing izalontamab brengitecan in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This trial is a registrational randomized, open-label, multicenter Phase II/III study designed to evaluate the efficacy and safety of BL-B01D1 in combination with a PD-1/VEGF bispecific antibody in patients with locally advanced or metastatic non-squamous non-small cell lung cancer.

03

Conditions studied

  • Non-squamous Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign the form and comply with the protocol requirements;
  2. Age ≥ 18 years;
  3. Expected survival time ≥ 3 months;
  4. Patients with locally advanced non-squamous non-small cell lung cancer;
  5. Agree to provide tumor tissue samples obtained at or after diagnosis of locally advanced or cancer;
  6. Must have at least one as defined by v1.1;
  7. performance status score of 0 or 1;
  8. Toxicities from prior anti-tumor therapy have recovered to ≤ Grade 1 as defined by v6.0;
  9. No severe cardiac dysfunction, with ≥ 50%;
  10. Organ function levels must meet the required criteria;
  11. Urinary protein ≤ 2+ or \< 1000 mg/24h;
  12. For premenopausal women of , a pregnancy test must be performed within 7 days before starting treatment; serum pregnancy test must rule out pregnancy; patients must be non-lactating and must use highly effective measures throughout the treatment period and for 7 months after the last dose. For male participants whose partners are women of childbearing potential, adequate barrier contraceptive measures must be used throughout the treatment period and for 7 months after the end of treatment.

Exclusion criteria

Exclusion Criteria:

  1. Presence of small cell lung cancer, neuroendocrine carcinoma, sarcomatoid carcinoma components, or squamous carcinoma components exceeding 10%;
  2. Evidence suggesting the presence of EGFR-sensitive mutations, etc.;
  3. Patients who have received prior systemic therapy;
  4. Prior receipt of therapies targeting the mechanism of tumor immunity;
  5. Prior receipt of antibody-drug conjugates (ADCs) using topoisomerase I inhibitors as the toxin, etc.;
  6. Trial participants who have received prior systemic anti-angiogenic therapy;
  7. Receipt of radical radiotherapy, major surgery, or large-field radiotherapy within 4 weeks before study randomization;
  8. History of severe cardiac or cerebrovascular disease;
  9. Receiving long-term systemic therapy (e.g., >10 mg/day prednisone) prior to the first dose;
  10. Active diseases and inflammatory diseases;
  11. Unstable thrombotic events requiring therapeutic intervention within 6 months before screening;
  12. Prolonged , complete left bundle branch block, etc.;
  13. Diagnosis of active within 3 years before study randomization;
  14. Hypertension poorly controlled by two antihypertensive medications;
  15. Patients with poorly controlled blood glucose;
  16. History of ILD requiring steroid therapy, current ILD, or ≥ grade 2 radiation pneumonitis, etc.;
  17. Concurrent pulmonary diseases resulting in clinically severe impairment of respiratory function;
  18. Patients with active central nervous system ;
  19. Occurrence of severe infection within 4 weeks before study randomization;
  20. Presence of large serous cavity effusions, or symptomatic serous cavity effusions, etc.;
  21. Imaging findings suggesting tumor invasion or encasement of abdominal, thoracic, or other regions;
  22. Presence of serious non-healing wounds, ulcers, or fractures within 4 weeks before signing ;
  23. Trial participants with bleeding or obvious bleeding tendency within 4 weeks before signing informed consent;
  24. Patients with a history of inflammatory bowel disease, extensive bowel resection, immune-mediated enteritis, intestinal obstruction, or chronic diarrhea, etc.;
  25. History of allergy to recombinant humanized antibodies or allergy to the drug, etc.;
  26. History of or allogeneic stem cell transplantation;
  27. Positive for antibody, active virus infection, or virus infection;
  28. History of severe neurological or psychiatric disorders;
  29. Receipt of other unapproved investigational drugs or treatments within 4 weeks before study randomization;
  30. Trial participants who plan to receive or have received within 28 days before study randomization;
  31. Other conditions that, in the investigator's opinion, make the patient unsuitable for participation in this clinical trial due to complications or other circumstances.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
166 participants (estimated)

Study arms

  • Experimental
    BL-B01D1 + PD-1/VEGF Bispecific Antibody

    Participants receive BL-B01D1 + PD-1/VEGF Bispecific Antibody in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

    Drug: BL-B01D1 · Drug: PD-1/VEGF Bispecific Antibody

  • Active comparator
    PD-1/VEGF Bispecific Antibody + Pemetrexed + Carboplatin or Cisplatin

    Participants receive PD-1/VEGF Bispecific Antibody + Pemetrexed + Carboplatin or Cisplatin in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

    Drug: PD-1/VEGF Bispecific Antibody · Drug: Pemetrexed · Drug: Carboplatin · Drug: Cisplatin

  • Active comparator
    Tislelizumab + Pemetrexed + Carboplatin or Cisplatin

    Participants receive Tislelizumab + Pemetrexed + Carboplatin or Cisplatin in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

    Drug: Tislelizumab · Drug: Pemetrexed · Drug: Carboplatin · Drug: Cisplatin

Interventions

  • Administration by intravenous infusion for a cycle of 3 weeks.

    Also known as: iza-bren, izalontamab brengitecan, BMS-986507

  • DrugPD-1/VEGF Bispecific Antibody

    Administration by intravenous infusion for a cycle of 3 weeks.

  • Administration by intravenous infusion for a cycle of 3 weeks.

  • Administration by intravenous infusion for a cycle of 3 weeks.

  • Administration by intravenous infusion for a cycle of 3 weeks.

  • Administration by intravenous infusion for a cycle of 3 weeks.

06

What researchers measure

Primary outcomes

  1. Phase II Part_A: Treatment Emergent Adverse Event (TEAE)

    TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of BL-B01D1. The type, frequency and severity of TEAE will be evaluated during the treatment of BL-B01D1.

    Time frame: Up to approximately 24 months

  2. Phase II Part_B: Objective Response Rate (ORR)

    Objective response rate (ORR) is defined as the number of CR and PR in the treatment and control groups divided by the number of that group in the full analysis set (FAS).

    Time frame: Up to approximately 24 months

  3. Phase III: BICR-assessed Progression-free Survival (PFS)

    Progression-free survival (PFS) as assessed by BICR is defined as the time between the date subjects were randomized and the first observation of disease progression (based on BICR's image-based assessment) or death.

    Time frame: Up to approximately 24 months

  4. Phase III: Overall Survival (OS)

    Overall survival (OS) is defined as the time between the day the subject is randomized and the subject's death.

    Time frame: Up to approximately 24 months

Secondary outcomes

  1. Phase II/III: Objective Response Rate (ORR)

    Objective response rate (ORR) is defined as the number of CR and PR in the treatment and control groups divided by the number of that group in the full analysis set (FAS).

    Time frame: Up to approximately 24 months

  2. Phase II/III: Disease Control Rate (DCR)

    Disease Control Rate (DCR) : Percentage of all randomized subjects who rated the best overall response (BOR) as complete response (CR), partial response (PR), and disease stabilization (SD) according to RECIST 1.1 criteria.

    Time frame: Up to approximately 24 months

  3. Phase II/III: Duration of Response (DOR)

    Duration of Response (DOR) : defined as the period from the date when tumor response is first recorded to the date when objective tumor progression is first recorded or the date of death.

    Time frame: Up to approximately 24 months

  4. Phase II/III: Progression-free Survival (PFS)

    Progression-free survival (PFS) as assessed by BICR is defined as the time between the date subjects were randomized and the first observation of disease progression (based on BICR's image-based assessment) or death.

    Time frame: Up to approximately 24 months

  5. Phase II Part_B/III: Treatment Emergent Adverse Event (TEAE)

    TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of BL-B01D1. The type, frequency and severity of TEAE will be evaluated during the treatment of BL-B01D1.

    Time frame: Up to approximately 24 months

  6. Phase II/III: Cmax

    Cmax is defined as the maximum observed drug concentration in plasma after administration.

    Time frame: Up to approximately 24 months

  7. Phase II/III: Tmax

    Tmax is defined as the time required to reach the maximum drug concentration in plasma following drug administration.

    Time frame: Up to approximately 24 months

  8. Phase II/III: T1/2

    T1/2 is defined as the time required for the plasma concentration of a drug to decrease by 50% during the elimination phase.

    Time frame: Up to approximately 24 months

  9. Phase II/III: AUC0-t

    AUC0-t is defined as area under the serum concentration-time curve from time 0 to the time of the last measurable concentration.

    Time frame: Up to approximately 24 months

  10. Phase II/III: CL (Clearance)

    Clearance (CL) is the volume of plasma from which a drug is completely removed per unit time.

    Time frame: Up to approximately 24 months

  11. Phase II/III: Ctrough

    Ctrough is defined as the lowest serum concentration prior to the next dose will be administered.

    Time frame: Up to approximately 24 months

  12. Phase II/III: Anti-drug Antibody (ADA)

    Anti-drug Antibody (ADA) refers to endogenous antibodies generated in subjects that specifically bind to the investigational drug.

    Time frame: Up to approximately 24 months

  13. Phase III: Neutralizing Antibody(NAb)

    Frequency of anti-BL-B01D1 neutralizing antibodies will be investigated.

    Time frame: Up to approximately 24 months

07

Study locations

2 of 2 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Dec 2029, 38 months after the start.

Of 56 phase 2/3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 40. This study's planned 38 months is below that.

Start moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, last on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2026
First posted
Jul 31, 2026
StartActual
Oct 21, 2026was Aug 2026
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 12, 2026
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Sun Yat-sen University Cancer Center · Guangzhou, Chinano status→Recruiting
  • The First Affiliated Hospital of Guangzhou Medical University · Guangzhou, Chinano status→Recruiting
Nov 12, 2026
Start date
Aug 2026→Oct 21, 2026 (actual)
moved 2 times, Oct 28, 2026 – Nov 12, 2026
Enrollment
120→166
Oct 28, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedPhase II Part_B: Objective Response Rate (ORR)Time frame: Up to approximately 24 months
  • ChangedBefore Phase II: Investigator-assessed Progression-free Survival (PFS)Now Phase II Part_A: Treatment Emergent Adverse Event (TEAE)Time frame: Up to approximately 24 months
Oct 28, 2026
Secondary outcomes
10 edited
What changed in the outcomes
  • EditedPhase II/III: Treatment Emergent Adverse EventObjective Response Rate (TEAEORR)Time frame: Up to approximately 24 months
  • EditedPhase II/III: Progression-free Survival (PFS)Time frame: Up to approximately 24 months
  • EditedPhase II/III: CmaxTime frame: Up to approximately 24 months
  • EditedPhase II/III: TmaxTime frame: Up to approximately 24 months
  • EditedPhase II/III: T1/2Time frame: Up to approximately 24 months
  • EditedPhase II/III: AUC0-tTime frame: Up to approximately 24 months
  • EditedPhase II/III: CL (Clearance)Time frame: Up to approximately 24 months
  • EditedPhase II/III: CtroughTime frame: Up to approximately 24 months
  • EditedPhase II/III: Anti-drug Antibody (ADA)Time frame: Up to approximately 24 months
  • ChangedBefore Phase III: BICR and Investigator-assessed Objective Response Rate (ORR)Now Phase II Part_B/III: Treatment Emergent Adverse Event (TEAE)Time frame: Up to approximately 24 months
Oct 28, 2026
Show all 2 updates
  1. Nov 12, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Sun Yat-sen University Cancer Center · Guangzhou, Chinano status→Recruiting
    • The First Affiliated Hospital of Guangzhou Medical University · Guangzhou, Chinano status→Recruiting
    Start date Nov 2026→Oct 21, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 28, 2026
    Start date Aug 2026→Nov 2026
    Enrollment 120→166
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedPhase II Part_B: Objective Response Rate (ORR)Time frame: Up to approximately 24 months
    • ChangedBefore Phase II: Investigator-assessed Progression-free Survival (PFS)Now Phase II Part_A: Treatment Emergent Adverse Event (TEAE)Time frame: Up to approximately 24 months
    Secondary outcomes 10 edited
    What changed in the outcomes
    • EditedPhase II/III: Treatment Emergent Adverse EventObjective Response Rate (TEAEORR)Time frame: Up to approximately 24 months
    • EditedPhase II/III: Progression-free Survival (PFS)Time frame: Up to approximately 24 months
    • EditedPhase II/III: CmaxTime frame: Up to approximately 24 months
    • EditedPhase II/III: TmaxTime frame: Up to approximately 24 months
    • EditedPhase II/III: T1/2Time frame: Up to approximately 24 months
    • EditedPhase II/III: AUC0-tTime frame: Up to approximately 24 months
    • EditedPhase II/III: CL (Clearance)Time frame: Up to approximately 24 months
    • EditedPhase II/III: CtroughTime frame: Up to approximately 24 months
    • EditedPhase II/III: Anti-drug Antibody (ADA)Time frame: Up to approximately 24 months
    • ChangedBefore Phase III: BICR and Investigator-assessed Objective Response Rate (ORR)Now Phase II Part_B/III: Treatment Emergent Adverse Event (TEAE)Time frame: Up to approximately 24 months
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07739186
Collaborators
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Jul 31, 2026
Start date
Oct 21, 2026
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Sa Xiao, PHD
Contact
xiaosa@baili-pharm.com
15013238943

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Izalontamab brengitecan

Start the discussion